Vesicor Therapeutics, Inc.

S-4/A amended

S-4/A amended

S-4/A amended

S-4/A amended

S-4/A amended

The current S-4/A filing details Black Hawk Acquisition Corporation's plan to merge with Vesicor Therapeutics, Inc., involving a domestication from the Cayman Islands to Delaware and a business combination. Key updates include late extension payments for the business combination deadline, a breach of governance terms, and ongoing efforts to complete the merger despite legal uncertainties. The filing also outlines capital structure changes, convertible note terms, and the continuation of shareholder approvals.

S-4/A amended

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation, involving a domestication from the Cayman Islands to Delaware and a merger. The filing details extensions to the business combination deadline, late payments for these extensions, and the subsequent resolution. The company addresses risks related to delayed payments, potential liquidation, and legal claims, while proceeding with the merger and shareholder approvals.

S-4/A amended

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation (SPAC), involving a merger and domestication from the Cayman Islands to Delaware. The transaction includes a share conversion, issuance of PubCo Common Stock, and assumption of warrants. The filing outlines the extension of the business combination timeline, funding through convertible notes, and the rebranding to Vesicor Therapeutics Holdings, Inc. following the merger.

S-4/A amended

The current S-4/A filing details Black Hawk Acquisition Corporation's plan to merge with Vesicor Therapeutics, Inc., involving a domestication from the Cayman Islands to Delaware and a subsequent merger. The transaction includes share conversions, trust account adjustments, and extension payments to delay the business combination deadline. The filing also outlines compensation for the Sponsor and risks related to the merger's completion and shareholder returns.

S-4 filed

Vesicor Therapeutics, Inc. is undergoing a business combination with Black Hawk Acquisition Corporation (SPAC), involving a merger and domestication from the Cayman Islands to Delaware. The transaction includes a name change to Vesicor Therapeutics Holdings, Inc., securities conversion, and redemption of public shares. The SPAC plans to extend the business combination timeline via convertible notes funded by the Sponsor, with $750,000 already deposited into the Trust Account.

DRS/A amended

Vesicor Therapeutics, Inc. filed a DRS/A on 2025-09-23, highlighting recent financial performance, business combination payments, and updates on clinical trial processes. The company reported increased operating expenses, a net loss of $141,176 for Q1 2025, and revenue from limited microvesicle-based product sales. It issued 258,668 units in a private placement, raising $485,000, and made payments related to its business combination. The filing emphasizes ongoing challenges with FDA regulatory approval, financial sustainability, and the risks of clinical trial delays and commercialization hurdles.

DRS/A amended

Vesicor Therapeutics, Inc. is seeking regulatory approval for its ecm-RV/p53 product candidate, which remains in early development with no clinical trials or commercial approvals achieved. The company highlights significant uncertainties around regulatory acceptance, competitive challenges, reimbursement viability, intellectual property protection, and clinical trial success. Key risks include FDA discretion in approvals, unproven therapeutic efficacy, and substantial development costs. The company anticipates no regulatory review initiation before late 2026.